📰 4 sources covering this story

Personalized cancer vaccine from Moderna, Merck shows promise in first late-stage melanoma trial

First covered 1 hrs ago · latest take 45 mins ago. Compare how each outlet is covering it — and rate the sources you trust.

Personalized cancer vaccine from Moderna, Merck shows promise in first late-stage melanoma trial
CNBC
CNBC1 hrs ago
Personalized cancer vaccine from Moderna, Merck shows promise in first late-stage melanoma trial
The combination regimen significantly extended the time patients lived without their melanoma returning, compared with Keytruda alone.
Quartz
Quartz45 mins ago
Moderna and Merck's personalized skin cancer vaccine cleared its first large-scale trial
The mRNA-based vaccine combined with Keytruda reduced melanoma recurrence in more than 1,100 patients whose cancer had been surgically removed
Reuters
Reuters1 hrs ago
Merck, Moderna say melanoma vaccine meets goals in large trial
Merck, Moderna say melanoma vaccine meets goals in large trial  Reuters
STAT News
STAT News🏁 first to report1 hrs ago
STAT+: Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial
A personalized mRNA cancer vaccine succeeded in a late-stage melanoma study, results that could herald a new, powerful approach in oncology.
Top rated outlets
Outlets are ranked once they have 3+ community ratings — be one of the first to rate.
🏆 Most trusted sources 2026 →
Scores come entirely from reader ratings — rate the sources you read to shape them. How it works →